Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in refractory or relapsed severe aplastic anemia (China, phase II)
CTR20192327Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eltrombopag in severe aplastic anemia (SAA), sponsored by Novartis. Started Nov 2019; status: completed.
02
Drugs
eltrombopag
03
Conditions
severe aplastic anemia (SAA)
Beyond the preview
Go deeper on CTR20192327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192327.